BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
63.36
-0.52 (-0.81%)
At close: Jan 31, 2025, 4:00 PM
63.09
-0.27 (-0.43%)
After-hours: Jan 31, 2025, 5:18 PM EST
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,401 employees as of December 31, 2023. The number of employees increased by 319 or 10.35% compared to the previous year.
Employees
3,401
Change (1Y)
319
Growth (1Y)
10.35%
Revenue / Employee
$809,412
Profits / Employee
$94,764
Market Cap
12.08B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BMRN News
- 9 days ago - BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy - Seeking Alpha
- 19 days ago - BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court - PRNewsWire
- 26 days ago - BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA - PRNewsWire
- 2 months ago - Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call - Seeking Alpha
- 2 months ago - BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 - PRNewsWire
- 3 months ago - BioMarin to Participate in Three Upcoming Investor Conferences - PRNewsWire
- 3 months ago - BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook - PRNewsWire